This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

PATH Resources

Our online catalog indexes publications, presentations, and related resources for peers in our field.

20 Resources
20 Resources
20 Resources
    Date
  1. Cryptosporidium is a leading cause of pediatric diarrhea in resource-limited settings; yet, few studies report the health care costs or societal impacts of this protozoan parasite. This study examined direct and indirect costs associated with symptomatic cryptosporidiosis in infants younger than 12 months in Kenya, Peru and Bangladesh.
    Published: January 2017
    Type: Resource Page
  2. Host antisecretory targets are a promising treatment option for easing the symptoms of diarrheal disease and addressing shortcomings of existing therapies. This poster presentation from the American Society of Tropical Medicine and Hygiene 2016 Annual Meeting summarizes the results of tests comparing several clinical-stage drug candidates that have the potential to treat acute secretory diarrhea.
    Published: November 2016
    Type: Resource Page
  3. PATH, in collaboration with the Epidemiology & Disease Control Division, Government of Nepal, and B.P. Koirala Institute of Health Sciences, Dharan, is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Nepal. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.
    Published: May 2016
    Type: Resource Page
  4. PATH, in collaboration with the Directorate General Health Services (DGHS), Directorate General Drug Administration (DGDA), Government of Bangladesh (GoB) and International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Bangladesh. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.
    Published: April 2016
    Type: Resource Page
  5. This infographic illustrates the key achievements of the project to establish and validate a manufacturing process to produce semisynthetic artemisinin (ssART) at industrial scale and commercialize ssART. Production of ssART aims to supplement a historically volatile botanical supply chain, strengthening the artemisinin market and ensuring that the global need for artemisinin-based combination therapies can be met, thus supporting current worldwide malaria control measures and strategies for malaria elimination.
    Published: April 2016
    Type: Resource Page
Load more